title: rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells.
abstract: Considerable evidence in preclinical models as well as in human transplantation now suggests that donor-derived natural killer (NK) cells can contribute to alloimmune recognition of recipient residual tumour cells. This makes the NK cell population an attractive target for in vitro or in vivo manipulations, in order to improve the antitumour effect of allogeneic transplantation. However, conditions in which allogeneic donor cells are collected vary; several reports have emphasised the different phenotypic and functional properties of T cells derived from marrow, cord blood or mobilised peripheral blood grafts; others have demonstrated different clinical outcomes following blood or marrow transplantation after myeloablative conditioning regimens. NK cells have been examined in this setting; the availability of new tools to study the expression of a variety of surface antigens that are involved in the control of NK cell activity offered us an opportunity to extensively characterise the phenotypic properties of NK cells from donors, before and after administration of pharmacological doses of rhG-CSF used for haematopoietic progenitor mobilisation. Our study suggests that rhG-CSF does not reproducibly alter blood NK cell phenotype in normal individuals, and thus that donor-derived cells are fully equipped to exert their potential antitumour effect.
authors.affiliation: Centre de Thérapie Cellulaire et Génique, Département de Biologie, Institut Paoli-Calmettes, Centre Régional de Lutte Contre le Cancer, Provence-Alpes-Côte d'Azur, 232 bd. Sainte Marguerite, 13273 Marseille cedex 9, France. lassailyf@marseille.fnclcc.fr
authors.forename: F
authors.initials: F
authors.lastname: Lassailly
authors.forename: I
authors.initials: I
authors.lastname: Sielleur
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: C
authors.initials: C
authors.lastname: Chabannon
mesh_terms: D001782:Blood Donors; D001854:Bone Marrow Cells / Q000166:cytology; D017252:CD3 Complex / Q000096:biosynthesis; D019002:CD56 Antigen / Q000096:biosynthesis; D005312:Fetal Blood / Q000166:cytology; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D007694:Killer Cells, Natural / Q000166:cytology*; D009369:Neoplasms / Q000628:therapy; D010641:Phenotype; D017452:Receptors, IgG / Q000096:biosynthesis; D011994:Recombinant Proteins; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D017252:CD3 Complex; D019002:CD56 Antigen; D017452:Receptors, IgG; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor